protocol

Latest stories

  • in Health care

    Revise Phase I/II CT protocol: CDSCO panel tells Serum Institute of India on Dengue Tetravalent Vaccine

    Revise Phase I/II CT protocol: CDSCO panel tells Serum Institute of India on Dengue Tetravalent Vaccine

    by

    New Delhi: Regarding the Phase I/II clinical trial of Dengue Tetravalent Vaccine (Live, Attenuated), the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the vaccine major Serum Institute of India to revise the Phase I/II clinical trial protocol. This came after the firm presented its proposal to conduct of […] More

  • in Health care

    Revise Phase III CT protocol: CDSCO Panel Tells Dr Reddy’s over Tegoprazan

    Revise Phase III CT protocol: CDSCO Panel Tells Dr Reddy's over Tegoprazan

    by

    New Delhi: In response to the proposal to conduct a Phase III clinical trial presented by the drug major Reddy’s Laboratories, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the firm to revise the protocol of Phase III clinical trial of the drug Tegoprazan with respect to the […] More

  • in Health care

    Revise Phase IV CT Protocol: CDSCO panel tells Zydus Lifesciences on Typhoid Vi Conjugate Vaccine with Yellow Fever Vaccine

    Revise Phase IV CT Protocol: CDSCO panel tells Zydus Lifesciences on Typhoid Vi Conjugate Vaccine with Yellow Fever Vaccine

    by

    New Delhi: In response to the drug major Zydus Life Sciences’ proposal to conduct Phase IV clinical for Typhoid Vi Conjugate Vaccine I.P.(TCV) with Yellow Fever Vaccine(YFV), the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the firm to revise the Phase IV clinical trial protocol. This came after […] More

  • in Health care

    CDSCO Panel Grants Abbott’s Protocol Amendment Proposal For Ursodeoxycholic Acid

    CDSCO Panel Grants Abbott's Protocol Amendment Proposal For Ursodeoxycholic Acid

    by

    New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has accepted Abbott’s phase III clinical trial protocol amendment proposal for Ursodeoxycholic Acid Tablets IP 150 mg, 300 mg, 450 mg, and 600 mg with respect to inclusion and exclusion criteria. Ursodeoxycholic acid, or ursodiol, is a naturally occurring […] More

  • SushiSwap DeFi Protocol Loses $3 Million in Exploit, Here’s What is Known About It

    by

    SushiSwap, a DeFi protocol, was exploited over the weekend that resulted in the loss of $3.3 million (roughly Rs. 27.03 crore). As per blockchain firms CertiK and Peckshield, a smart contract around function approvals was exploited by hackers to facilitate this attack on April 9. Researchers have claimed that SushiSwap users who engaged with the […] More

  • in Health care

    CDSCO panel approves Reliance Life Science’s Phase III CT Protocol for Tocilizumab

    CDSCO panel approves Reliance Life Science's Phase III CT Protocol for Tocilizumab

    by

    New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved Reliance Life Science’s Phase III clinical trial protocol of immunosuppressive Tocilizumab with some changes in exclusion criteria. This came after the firm presented the proposal to conduct a Phase III clinical trial titled “A prospective, multicenter, randomized, […] More

  • in Health care

    Submit revised BE study protocol: CDSCO panel tells Laurus Labs on Carglumic Acid Dispersible Tablets

    by

    New Delhi: Rejecting drug maker Laurus Lab’s proposal for clinical trial waiver of Carglumic acid dispersible tablets 200mg, the subject committee expert (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to submit a revised bioequivalence (BE) study protocol by capturing complete details such as the objective of the study, […] More